Form 4 for CORT CORCEPT THERAPEUTICS INC
Accepted 2026-07-06 16:44:28 ET · period of report 2026-07-01 · accession 0001193125-26-296296 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-06 16:44 | 2026-07-01 | CORT | Maduck Sean | See Remarks | M - OptEx | $8.27 | +25.0K | 34.8K | +256% | +$206.8K |
| DMT | 2026-07-06 16:44 | 2026-07-01 | CORT | Maduck Sean | See Remarks | S - Sale+OE | $88.35 | -25.0K | 9,755 | -72% | -$2.21M |
| DT | 2026-07-06 16:44 | 2026-07-01 | CORT | Maduck Sean | See Remarks | M - OptEx | $0.00 | -25.0K | 117.0K | -18% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-01 | M | A | 25,000 | $8.27 | 34,755 | D | — | — | (F1) Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 2 | Common | Common Stock | 2026-07-01 | S | D | 11,024 | $87.33 | 23,731 | D | — | — | (F2) This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction. (F3) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $86.95 to $87.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. (F1) Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 3 | Common | Common Stock | 2026-07-01 | S | D | 2,801 | $88.51 | 20,930 | D | — | — | (F2) This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction. (F4) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $87.98 to $88.97 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. (F1) Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 4 | Common | Common Stock | 2026-07-01 | S | D | 11,175 | $89.31 | 9,755 | D | — | — | (F2) This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction. (F5) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $89.09 to $89.37 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. (F1) Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 5 | Derivative | Stock option (right to buy) | 2026-07-01 | M | D | 25,000 | $0.00 | 116,986 | D | $8.27 · — to 2027-02-10 | 25,000 Common Stock | (F11) Fully exercisable. |